HomePipelinePNB-028

Second clinical molecule

PNB-028

Clinical · Phase 1/2a ongoing

A targeted oncology molecule in a DCGI-approved combined Phase 1/2 trial for pancreatic and Colorectal Cancer, with Acute Pancreatitis as a further target-based indication.

Indications

Each indication opens its study.

Stage of development

  • PNB-028

    Pancreatic CancerCCK inhibition via the CCK-C receptor

  • PNB-028

    Colon CancerCCK inhibition via the CCK-C receptor

  • PNB-028

    PancreatitisInhibition of pancreatic enzymes

Graph of the stage of development of each PNB-028 programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Target and mechanism
CCK-C isoform-selective, irreversible antagonist binding the receptor's extracellular loop. Described by the company as the first irreversible CCK-C antagonist.
Key findings

In nude-mouse xenograft models, PNB-028 completely inhibited growth of chemo-resistant MAC16 colon tumours and MIA PaCa pancreatic tumours. Tumours in treated animals stayed organ-confined, while untreated tumours spread to the lungs, and treated animals did not become cachectic.

Across six Colon Cancer cell lines, all expressing CCK receptors, PNB-028 inhibited cancer-cell growth without affecting normal cell lines.

In cerulein- and sincalide-induced Acute Pancreatitis models, protection was seen from 1 mg/kg, with dose-dependent reductions in inflammation and swelling.

Development

More than 80% oral bioavailability in rats; stable in rat, dog and human liver microsomes.

Two-step synthesis from economical raw materials, purity above 99.8%; five kilograms made for regulatory studies. ICH toxicology and safety pharmacology completed.

Intellectual property
Patents filed in the US, Europe and rest of world; PCT application filed and granted; USPTO patent issued 28 December 2014.
PNB-028 clinical trials

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.